CHA News

FDA Authorizes Booster Doses for Moderna, Johnson & Johnson COVID-19 Vaccines 

For CEOs, CMOs, CNOs, COOs, and infection prevention, quality & patient safety, employee safety staff

This post has been archived and contains information that may be out of date.

The Food and Drug Administration (FDA) has amended emergency use authorization (EUA) for COVID-19 vaccines to allow booster doses for the Moderna and Johnson & Johnson vaccines. Specifically, the EUA allows for a single-dose booster in the following circumstances: 

  • The use of a single booster dose of the Moderna COVID-19 vaccine may be administered at least six months after completion of the primary series to individuals: 
    • Ages 65 and older
    • Ages 18-64 at high risk of severe COVID-19 
    • Ages 18-64 with frequent institutional or occupational exposure to SARS-CoV-2 
  • The use of a single booster dose of the Johnson & Johnson COVID-19 vaccine may be administered at least two months after completion of the single-dose primary regimen to individuals ages 18 older. 

The FDA also authorizes a heterologous (or “mix and match”) booster dose in eligible individuals following completion of primary vaccination with a different available COVID-19 vaccine.